Microfracture With/Without Collagen Augmentation in Patients Undergoing High Tibial Osteotomy
Launched by THE CATHOLIC UNIVERSITY OF KOREA · Feb 14, 2016
Trial Information
Current as of June 14, 2025
Unknown status
Keywords
ClinConnect Summary
CartiFill™ (atelocollagen, Sewon Cellontech, Seoul, Korea) was developed to to provide a matrix stability and to maintain the blood clot in the defect site, which promoted the cartilage regeneration by mesenchymal stem cell . It was a atelocollagen, highly purified porcine derived type collagen І that has been modified to virtually eliminate the risk of rejection by removal of telopeptide.
The investigators randomized patients undergoing HTO in combination with microfracture to receive either microfracture alone (control group, n = 5) or microfracture with collagen augmentation (experiment...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged below 65 years with isolated medial compartment osteoarthritis
- • Good range of motion
- • No ligament instability
- • Having medicare insurance
- Exclusion Criteria:
- • Diagnosis of severe tricompartment osteoarthritis indicated for total knee arthroplasty
- • Inflammatory arthritis(rheumatoid arthritis), osteonecrosis
- • Flexion contracture ≥ 15°
- • Knee range of motion \< 120°
- • Joint instability
- • A history of knee joint infection and who refused to participate
About The Catholic University Of Korea
The Catholic University of Korea is a prestigious academic institution dedicated to advancing medical research and healthcare innovation. With a commitment to ethical standards and clinical excellence, the university actively sponsors clinical trials aimed at improving patient outcomes and enhancing medical knowledge. Its multidisciplinary approach fosters collaboration among experts in various fields, ensuring rigorous study design and comprehensive analysis. The Catholic University of Korea is dedicated to contributing significantly to the global medical community through its research initiatives and commitment to the highest standards of scientific integrity.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Yong In, MD, PhD
Study Chair
the Catholic Univerisity of Korea Seoul St Mary's hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials